Progyny, Inc. (NASDAQ:PGNY) Shares Sold by US Bancorp DE

US Bancorp DE lessened its stake in Progyny, Inc. (NASDAQ:PGNY) by 17.9% in the 3rd quarter, Holdings Channel reports. The firm owned 9,001 shares of the company’s stock after selling 1,957 shares during the period. US Bancorp DE’s holdings in Progyny were worth $151,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Progyny by 0.5% in the first quarter. Vanguard Group Inc. now owns 8,311,840 shares of the company’s stock valued at $317,097,000 after purchasing an additional 41,687 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Progyny by 1,576.0% during the 3rd quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company’s stock valued at $42,991,000 after acquiring an additional 2,412,068 shares in the last quarter. Farallon Capital Management LLC lifted its position in Progyny by 120.8% during the second quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock worth $37,436,000 after buying an additional 715,900 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Progyny by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company’s stock valued at $36,676,000 after buying an additional 254,725 shares during the period. Finally, Kornitzer Capital Management Inc. KS raised its holdings in Progyny by 8.2% in the second quarter. Kornitzer Capital Management Inc. KS now owns 843,829 shares of the company’s stock valued at $24,142,000 after buying an additional 63,795 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Trading Down 1.5 %

Progyny stock opened at $13.77 on Friday. The company has a market capitalization of $1.17 billion, a P/E ratio of 23.74, a P/E/G ratio of 1.31 and a beta of 1.44. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $42.08. The firm’s fifty day simple moving average is $17.30 and its 200-day simple moving average is $23.36.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm had revenue of $286.63 million during the quarter, compared to the consensus estimate of $296.85 million. During the same period in the prior year, the business earned $0.16 EPS. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. On average, equities research analysts predict that Progyny, Inc. will post 0.64 earnings per share for the current year.

Analyst Ratings Changes

PGNY has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of Progyny in a report on Tuesday, October 1st. Leerink Partners cut their price objective on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a research note on Thursday, September 19th. Canaccord Genuity Group decreased their price target on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday. Barclays decreased their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, JMP Securities lowered Progyny from an “outperform” rating to a “market perform” rating in a report on Thursday, September 19th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $25.42.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.